in for Reversal of Antiplatelet Drugs in Stroke as a consequence of Haemorrhage (DASH): Second

in for Reversal of Antiplatelet Drugs in Stroke as a consequence of Haemorrhage (DASH): Second Interim Report on Recruitment from a Phase II Double Blind Randomised Controlled Trial M. Desborough1,two,3; R. Al-Shahi Salman4; S. Stanworth1,two,five; D. Havard6; P.M Brennan4; R. Dineen6; T. Coats7; T. Hepburn8; L. Woodhouse6; P. Bath6; N. SpriggDepartment of Haematology, John Radcliffe Hospital, Oxford, UnitedKingdom; 2Oxford Clinical Investigation in Transfusion Medication, University of Oxford, Oxford, Uk; 3Centre for Haemostasis and PO161|Refractory Thrombotic Thrombocytopenic Purpura – A Case Report A. Aribandi ; C. Ranjith ; S. Sushma ; T. Surapaneni1 one one 2Thrombosis, Guy’s and St Thomas’ NHS Basis Believe in, London, Uk; 4Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United kingdom; 5NHS Blood and Transplant, Oxford, Uk; 6Stroke, Division of Clinical Neuroscience, University of Nottingham, Nottingham, United kingdom; 7Department of Cardiovascular Sciences, University of Leicester, Leicester, United kingdom; 8Clinical Trials Unit, University of Nottingham, Nottingham, Uk Background: Intracerebral haemorrhage induced around 3 million deaths globally in 2015. Pre-stroke antiplatelet drug use is related having a 27 relative boost in one-month case fatality when compared to patients not working with antithrombotic medicines. Aims: We aim to assess the feasibility of administering desmopressin or placebo to sufferers with antiplatelet associated intracerebral haemorrhage to inform the style of a definitive trial. Techniques: While in the ongoing DASH trial, we aim to involve 50 sufferers inside 24 hours of spontaneous intracerebral haemorrhage onset, associated with oral antiplatelet drug(s) use while in the preceding seven days (figure 1). This time window was initially set at twelve hours but was elevated on 01 December 2019 to maximise recruitment. Patients are randomised (one:1) to acquire intravenous desmopressin twenty ug in 50 ml sodium chloride 0.9 infused more than twenty minutes or matching placebo. Feasibility outcomes consist of proportion of patients approached being randomised, CDK5 Inhibitor MedChemExpress variety of patients getting Caspase 1 Chemical site allocated remedy, charge of recruitment, and adherence to treatment method and adhere to up. Secondary outcomes involve adjust in intracerebral haemorrhage volume at 24 hrs; early mortality 28 days, death or dependency at day 90, major adverse events up to day 90.American Oncology Institute, Hyderabad, India; 2FernandezFoundation, Hyderabad, India Background: Thrombotic thrombocytopenic purpura (TTP) is usually a uncommon life-threatening thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, thrombocytopenia, fever, Neurologic abnormalities, and acute renal insufficiency. Aims: To existing the diagnosis and management of a case of refractory thrombotic thrombocytopenic purpura. Procedures: Hematological and biochemical scientific studies had been performed .ADAMS 13 exercise antibodies were measured in our situation to detect TTP. Final results: 27 yr previous lady, G3A2, at 21 weeks six days, was diagnosed to get Intrauterine fetal demise, so termination of pregnancy was done and she was advised LMWH for 6 weeks post-delivery. On PND three she presented with C/O giddiness and burning micturition. On evaluation her CBC was 6gm/dl and platelets were 20000/mm3. Peripheral smear showed schistocytes with thrombocytopenia. PT APTT were standard. Empirical diagnosis of TTP was created and she was commenced on steroids and plasmapheresis. ADAMS 13 action wa